Drug Profile
EV 029105a
Alternative Names: EV029105aLatest Information Update: 28 Jul 2018
Price :
$50
*
At a glance
- Originator Evec
- Class Antibacterials; Monoclonal antibodies
- Mechanism of Action Immunostimulants
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- No development reported Clostridium difficile infections
Most Recent Events
- 28 Jul 2018 No recent reports of development identified for preclinical development in Clostridium-difficile-infections in Japan (Parenteral)
- 28 Jul 2018 No recent reports of development identified for preclinical development in Clostridium-difficile-infections(Prevention) in Japan (Parenteral)
- 06 Jul 2016 EV 029105a is available for licensing as of 06 Jul 2016. http://www.evec.jp/